Biohaven director trust buys 28,400 shares
Biohaven Ltd. director John W. Childs reported an amended insider transaction showing an indirect open‑market purchase of 28,400 Common Shares by the John W Childs 2013 Revocable Trust at a weighted average price of $30.4266 per share.
Rhea-AI Filing Summary
Biohaven Ltd. director John W. Childs reported an amended insider transaction showing an indirect open‑market purchase of 28,400 Common Shares by the John W Childs 2013 Revocable Trust at a weighted average price of $30.4266 per share.
The amendment corrects an earlier filing that had allocated 3,400 purchased shares to a 2013 Charitable Remainder Trust and 25,000 shares to the revocable trust. It clarifies that all 28,400 shares were acquired through the revocable trust, with no shares acquired through the charitable remainder trust in this transaction.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Shares | 28,400 | $30.4266 | $864K |
| holding | Common Shares | -- | -- | -- |
Footnotes (2)
- F1. This amendment is being filed to correct the nature of the indirect ownership reported in the Form 4 filed on March 5, 2025 (the "Original Form 4"). The Original Form 4 inadvertently misstated that 3,400 Common Shares were indirectly acquired by the Reporting Person through the 2013 Charitable Remainder Trust, and 25,000 Common Shares were indirectly acquired by the Reporting Person through the John W Childs 2013 Revocable Trust. However, as reflected in this amendment, 28,400 Common Shares were indirectly acquired by the Reporting Person through the John W Childs 2013 Revocable Trust, and no Common Shares were indirectly acquired by the Reporting Person through the 2013 Charitable Remainder Trust.
- F2. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $30.17 - $30.89, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote to this Form 4.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did John W. Childs report for Biohaven (BHVN)?
Why was the Biohaven (BHVN) Form 4/A filing by John W. Childs amended?
What price range did the Biohaven (BHVN) insider purchase by John W. Childs cover?
AI-generated analysis. How Rhea-AI works. Not financial advice.